Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Jan 27;16(1):e0246072. doi: 10.1371/journal.pone.0246072

Noninvasive ventilation in critically ill very old patients with pneumonia: A multicenter retrospective cohort study

Bruno A M P Besen 1,2,*, Marcelo Park 2, Otávio T Ranzani 3,4
Editor: Andrea Cortegiani5
PMCID: PMC7840033  PMID: 33503042

Abstract

Background

Very old patients (≥ 80 years-old, VOP) are increasingly admitted to intensive care units (ICUs). Community-acquired pneumonia (CAP) is a common reason for admission and the best strategy of support for respiratory failure in this scenario is not fully known. We evaluated whether noninvasive ventilation (NIV) would be beneficial compared to invasive mechanical ventilation (IMV) regarding hospital mortality.

Methods

Multicenter cohort study of VOPs admitted with CAP in need of IMV or NIV to 11 Brazilian ICUs from 2009 through 2012. We used logistic regression models to evaluate the association between the initial ventilatory strategy (NIV vs. IMV) and hospital mortality adjusting for confounding factors. We evaluated effect modification with interaction terms in pre-specified sub-groups.

Results

Of 369 VOPs admitted for CAP with respiratory failure, 232 (63%) received NIV and 137 (37%) received IMV as initial ventilatory strategy. IMV patients were sicker at baseline (median SOFA 8 vs. 4). Hospital mortality was 114/232 (49%) for NIV and 90/137 (66%) for IMV. For the comparison NIV vs. IMV (reference), the crude odds ratio (OR) was 0.50 (95% CI, 0.33–0.78, p = 0.002). This association was largely confounded by antecedent characteristics and non-respiratory SOFA (adjOR = 0.70, 95% CI, 0.41–1.20, p = 0.196). The fully adjusted model, additionally including Pao2/Fio2 ratio, pH and Paco2, yielded an adjOR of 0.81 (95% CI, 0.46–1.41, p = 0.452). There was no strong evidence of effect modification among relevant subgroups, such as Pao2/Fio2 ratio ≤ 150 (p = 0.30), acute respiratory acidosis (p = 0.42) and non-respiratory SOFA ≥ 4 (p = 0.53).

Conclusions

NIV was not associated with lower hospital mortality when compared to IMV in critically ill VOP admitted with CAP, but there was no strong signal of harm from its use. The main confounders of this association were both the severity of respiratory dysfunction and of extra-respiratory organ failures.

Introduction

The very old patients (≥ 80 years-old) (VOPs) are a subpopulation increasingly admitted to ICUs [1]. Common reasons for admission among VOPs are respiratory diagnoses [2], especially pneumonia, for which the initial strategy of respiratory support is controversial: while noninvasive ventilation (NIV) may be an option [3], it carries a risk of failure of up to 50% in this scenario [4, 5], which is associated with worse outcomes [6]. In contrast, invasive mechanical ventilation (IMV) and its downstream consequences such as sedation also carries the risk of important adverse events that could impact both mortality and functional outcomes.

The VOPs commonly have a high burden of comorbidities combined with impaired functional status [2, 7, 8] and frailty [2, 9], which pose a special challenge for the clinician upon treatment decision-making [10]. Indeed, VOP is prone to worse physiological abnormalities and higher risk of NIV failure [11]. By contrast, chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF) are common comorbidities in VOP and are known to benefit from NIV in acute respiratory failure [3, 12, 13], possibly even in patients with pneumonia [3].

The decision to provide organ support in VOPs involves more complex decision-making and may vary among intensivists [14]. While the elderly are reluctant to accept IMV as a reasonable life sustaining therapy [15], NIV may still be considered a reasonable option as ceiling therapy without detrimental effects on quality of life [16]. In this context, NIV in VOPs may allow for a less invasive strategy in a time-limited ICU trial [17, 18], which could suffice for decision making throughout the course of ICU stay while not lending these patients subject to unnecessary suffering and potential harms from IMV. However, data supporting the use of NIV in this subpopulation is scarce and recent research demonstrates sustained mortality rates despite antimicrobial availability (in pneumococcal pneumonia) and suggests non-antimicrobial strategies should be further evaluated [19].

Our objective was to evaluate the association between the initial ventilatory strategy of respiratory support–NIV or IMV–and hospital mortality in a representative sample of VOPs admitted to intensive care units with respiratory failure from community-acquired pneumonia (CAP) as main reason for ICU admission. We hypothesized that a less invasive strategy of organ support (NIV) would be beneficial in VOPs with pneumonia.

Material and methods

Study design, setting and ethical considerations

This is a multicenter retrospective cohort study between January, 2009 and December, 2012. There were 11 participating ICUs from a Brazilian network of private hospitals. One hospital is specialized in the care of heart diseases, while the others are mixed ICUs.

The Research and Ethics Committee of Hospital Pró-Cardíaco–the reference ethics committee designated by the National Research Ethics Committee–approved the retrospective analysis and publication of the data under the number 729.008 (CAAE: 33111214.3.0000.5533) and waived the need for informed consent given the retrospective nature of this study. We adhered to the STROBE guidelines (S1 File) and to the guidance from editors of respiratory, critical care and sleep journals [20].

Study population, exposures and outcome

The study population comprised very old patients (≥ 80 years old) admitted to the intensive care unit with CAP as the main reason for admission for whom invasive or noninvasive ventilation was deemed necessary. We excluded ICU readmissions. The exposure of interest was whether the initial respiratory support was NIV or IMV in the first day of ICU admission. The primary outcome was hospital mortality.

Data collection and definitions

We retrieved data from a prospectively collected multicenter ICU database (Epimed Monitor System®, Epimed Solutions®, Rio de Janeiro, Brazil), a cloud-based registry for ICU quality improvement in Brazil [21]. Data of all admitted patients are entered in the system by a trained case manager nurse and regularly audited. Retrieved variables included demographics (age and sex), body mass index, admission SAPS 3 [22], 1st day sequential organ failure assessment (SOFA) score [23], previous functional status [7], comorbidities (all those from the Charlson comorbidity index) [24], 1st hour physiological data (Pao2/Fio2 ratio, Paco2 and pH), use of organ support in the 1st hour, 1st 24 hours and throughout ICU stay (vasopressors, renal replacement therapy, IMV, NIV), ICU and hospital length-of-stay and mortality, and palliative care decision within 24 hours of ICU admission. We calculated the Pneumonia severity index (PSI) [25], the modified frailty index (MFI) [26] and whether the patients were septic or not (according to Sepsis 3.0 definitions) [27, 28] from available variables of the dataset.

Data analysis

Categorical variables are described as numbers and percentages. Quantitative variables are presented as means (standard deviations) or medians [25th percentile, 75th percentile] accordingly. Continuous variables were evaluated for normality with histograms and analyzed with t-tests when appropriate. Non-normal continuous variables and discrete variables were analyzed with the Wilcoxon rank-sum test. Categorical variables were analyzed with the chi-squared test or the Fisher exact test, as appropriate.

The choice of the initial treatment strategy is associated with several clinical conditions. As recommended by Lederer et al., we chose the set of potential confounding factors based on a directed acyclic graph (DAG), accounting for causal paths and avoiding mediators, open back-door paths and collider-bias [20] (S1 Fig). We ran multivariable logistic regression models adjusting for potential confounders with different sets of covariates at a time: model 1: age and sex; model 2: model 1 plus body mass index (a proxy for malnutrition), COPD, heart failure, dementia and performance status; model 3: model 2 plus non-respiratory SOFA and admission source; model 4 (main model): model 3 plus respiratory variables (Pao2/Fio2 < 150 mmHg, pH < 7.3, Paco2 > 50 mmHg).

We explored the robustness of the main model with four sensitivity analyses: 1) adding the SAPS 3 score in model 2, providing a different strategy to deal with severity and acuity variables spending less degrees of freedom; 2) excluding patients in whom palliative care was ascertained in the first day of ICU admission; 3) analyzing only patients admitted directly from the emergency department; and 4) running the main model (model 4) in complete case analysis. We also performed a post-hoc survival analysis censoring follow-up at 28 days of ICU admission. For this analysis, since we followed-up patients up to hospital discharge (or death), which would lead to informative censoring, we considered patients discharged alive as alive up to 28 days. We present results by their primary group (NIV vs. IMV) with a crude analysis (Kaplan-Meier survival curve and hazard ratios with 95% CIs from a univariate Cox model) and an adjusted analysis in a multivariable Cox model (adjusting for age, sex, modified frailty index and SAPS 3). We assessed proportional hazards by Schoenfeld residuals and log-log plots.

We evaluated effect modification by adding an interaction term in model 4 (main model) for ad-hoc defined subgroups: COPD, heart failure, severe functional status impairment, non-respiratory SOFA ≥ 4, Pao2/Fio2 ≤ 150 mmHg and acute respiratory acidosis (pH < 7.3 and Paco2 ≥ 50 mmHg). Cut-off values were based on standard values used in other studies and traditional indications for IMV (eg, acute respiratory acidosis).

We derived the marginal prediction from model 4 to illustrate the association between the initial strategy of ventilation and mortality in some scenarios. The marginal prediction represents the mortality predicted by the model if all patients in the cohort had received NIV or IMV in each scenario, while all other covariates are kept as observed [29]. We explored scenarios that contrasted the magnitude of extrapulmonary organ dysfunction [low (0), intermediate (4) vs. high (8) non-respiratory SOFA score]; functional status impairment (severe vs. non-severe); and hypoxemia (Pao2/Fio2 ratio > 150 or ≤ 150 mmHg). Furthermore, in an as-treated analysis, we evaluated the outcomes of patients of the NIV group who were intubated within or after 24 hours of ICU admission, and calculated adjusted odds ratios, adjusting for as model 4.

We conducted multiple imputations to deal with missing data in covariates [30]. We assumed data to be missing at random and imputed 50 datasets using chained equations with predictive mean matching. We included in the imputation model the outcome and exposure variables, all variables considered for covariate adjustment, interaction terms and auxiliary variables [31]. Further details of data missingness and the imputation model are described in the S1 Checklist.

We considered a p-value <0.05 as statistically significant for all analyses and no multiplicity adjustment was done. StataSE® version 16.0 was used for all analyses and the user-written mimrgns command was used to generate marginal effects.

Results

6,318 very old patients were admitted to the ICUs from Jan, 2009, to December, 2012. 678 patients were admitted due to CAP (S2 Fig), out of which 369 presented with respiratory failure (NIV, 232 [63%]; IMV, 137 [37%]) (Fig 1). Overall, median age was 86 [83; 89] years old and there was a higher proportion of female patients (55%). 31% of patients were severely impaired, while 45% were frail according to the MFI. Median SOFA was 5.5 [3; 8] and mean SAPS 3 was 68 (+/- 14). Table 1 describes the main characteristics of the study groups: there were no differences regarding antecedent characteristics; however, the IMV group differed regarding admission source and acuity variables, with higher non-respiratory SOFA scores, higher SAPS 3 scores, lower pH and lower Pao2/Fio2 ratio (Table 1). Overall hospital mortality was 55% (204/369): it ranged from 49% (114/232) in patients of the NIV group to 66% (90/137) for patients in the IMV group.

Fig 1. Flowchart of study participants from intensive care unit admission until the outcome (hospital death or discharge) according to the ventilation strategy.

Fig 1

ICU: Intensive care unit; IMV: Invasive Mechanical ventilation; NIV: Noninvasive ventilation; Failure: need for IMV within 24 hours of ICU admission. Success: no need for IMV within 24 hours of ICU admission.

Table 1. Patient characteristics at intensive care unit admission.

Variable All patients NIV * IMV p-value
N = 369 N = 232 N = 137
Age, years 86 [83; 89] 87 [83; 90] 86 [82; 89] 0.123
Male, n (%) 167 (45.3%) 101 (43.5%) 66 (48.2%) 0.387
Body mass index < 23 Kg/m2 100/252 (39.7%) 55/154 (35.7%) 45/98 (45.9%) 0.107
Charlson comorbidity index 2 [1; 3] 2 [1; 3] 2 [1; 3] 0.91
Comorbidities
    Hypertension 191 (51.8%) 123 (53%) 68 (49.6%) 0.53
    Diabetes 103 (27.9%) 60 (25.9%) 43 (31.4%) 0.25
    Heart failure 69 (18.7%) 48 (20.7%) 21 (15.3%) 0.202
    COPD 52 (14.1%) 28 (12.1%) 24 (17.5%) 0.146
    CKD § 46 (12.5%) 32 (13.8%) 14 (10.2%) 0.32
    Long-term dialysis 7 (1.9%) 3 (1.3%) 4 (2.9%) 0.27
    Cirrhosis 2 (0.5%) 2 (0.9%) 0 0.53
    Dementia 104 (28.2%) 65 (28%) 39 (28.5%) 0.93
    Cancer 35 (9.5%) 23 (9.9%) 12 (8.8%) 0.71
Performance status impairment 0.434
    Absent/Minor 118 (32%) 70 (30.2%) 48 (35%)
    Moderate 136 (36.9%) 91 (39.2%) 45 (32.9%)
    Severe 115 (31.2%) 71 (30.6%) 44 (32.1%)
Modified frailty index 0.985
    Non-frail (MFI || = 0) 27 (7.3%) 17 (7.3%) 10 (7.3%)
    Pre-frail (MFI || = 1–2) 176 (47.7%) 110 (47.4%) 66 (48.2%)
    Frail (MFI || ≥ 3) 166 (45%) 105 (45.3%) 61 (44.5%)
PSI IV/V 340 (92.1%) 205 (88.4%) 135 (98.5%) < 0.001
Sepsis 287 (79.7%) 163 (71.5%) 124 (93.9%) < 0.001
SAPS 3 ** 67.7 (14) 62.6 (11) 76.5 (14.2) < 0.001
SOFA †† 5.5 [3; 8] 4 [2; 7] 8 [6; 11] < 0.001
    Non-respiratory SOFA †† 4 [2; 7] 3 [1; 6] 7 [4; 9] < 0.001
    Non-respiratory SOFA ≥ 4 †† 193 (57.1%) 96/217 (44.2%) 97/121 (80.2%) < 0.001
Arterial blood gases
    pH < 7.3 62/241 (25.7%) 23/129 (17.8%) 39/112 (34.8%) 0.003
    Pao2/Fio2 ≤ 150 64/208 (30.8%) 21/102 (20.6%) 43/106 (40.6%) 0.002
    Acute respiratory acidosis 39/241 (16.2%) 15/129 (11.6%) 24/112 (21.4%) 0.039
Palliative care within 24h 25 (6.8%) 19 (8.2%) 6 (4.4%) 0.20
Admission source 0.015
    Emergency department 225 (61%) 143 (61.6%) 82 (59.9%)
    Ward 89 (24.1%) 64 (27.6%) 25 (18.3%)
    Other hospital 43 (11.7%) 19 (8.2%) 24 (17.5%)
    Other 12 (3.2%) 6 (2.6%) 6 (4.4%)
Other organ support
    Vasoactive drugs (24h) 123 (33.3%) 31 (13.4%) 92 (67.2%) < 0.001
    Vasoactive drugs (any) 167 (45.3%) 62 (26.7%) 105 (76.6%) < 0.001
    RRT i (24h) 5 (1.4%) 3 (1.3%) 2 (1.5%) >0.99
    RRT i (any) 22 (6%) 11 (4.7%) 11 (8%) 0.198

* Noninvasive mechanical ventilation

Invasive mechanical ventilation

Chronic obstructive pulmonary disease

§ Chronic kidney disease

|| Modified frailty index

Pneumonia severity index

** Simplified acute physiologic score 3rd version

†† Sequential organ failure assessment in the first 24 hours of ICU admission

‡‡ Renal replacement therapy.

The primary outcome analysis results are presented in Table 2. When comparing NIV and IMV as the initial respiratory support strategy, the sequential adjustment suggested the association was largely confounded by acuity variables. Indeed, the crude odds ratio (OR) was 0.50 (95% CI, 0.33–0.78, p = 0.002), and subsequently 0.70 (95% CI, 0.41–1.20, p = 0.196) for model 3 (antecedents plus non-respiratory SOFA) and 0.81 (95% CI, 0.46–1.41, p = 0.452) for model 4 (model 3 plus oxygenation and alveolar ventilation variables).

Table 2. Crude and adjusted odds ratios for hospital mortality between groups*.

OR (95% CI) p-value
Crude analysis 0.50 (0.33–0.78) 0.002
Model 1 0.47 (0.30–0.74) 0.001
Model 2 0.45 (0.29–0.72) 0.001
Model 3 § 0.70 (0.41–1.20) 0.196
Model 4 || 0.81 (0.46–1.41) 0.452

* Invasive mechanical ventilation is the referent group.

Model 1: adjusting for age and sex.

Model 2: adjusting for model 1 + antecedent characteristics (body mass index + comorbidities + functional status).

§ Model 3: adjusting for model 2 + non-respiratory SOFA + source.

|| Model 4: adjusting for model 3 + ABG variables (PaO2/FiO2 ratio, pH, Pco2).

We observed similar results in sensitivity analyses for the primary outcome comparing NIV vs. IMV (S2 Table): 1) adding SAPS 3 in the model yielded an adjOR of 0.77 (95% CI, 0.45–1.31, p = 0.34); 2) excluding patients with an early definition of palliative care (within 24 hours of ICU admission) yielded an adjOR of 0.78 (95% CI, 0.44–1.38, p = 0.39); 3) analyzing only patients admitted directly from the emergency department yielded an adjOR of 1.03 (95% CI, 0.51–2.08, p = 0.94); 4) analyzing only patients with PSI scores ≥ IV/V yielded an adjOR of 0.83 (95% CI, 0.47–1.46, p = 0.51); and 5) the complete case data analysis yielded an adjOR of 1.02 (95% CI, 0.40–2.64, p = 0.96). In a survival analysis framework (S3 and S4 Figs), the crude Hazard Ratio (HR) point-estimate was in line with results of Model 1 (HR = 0.75, 95% CI 0.55–1.02, p = 0.065). The adjusted analysis yielded an adjHR of 1.19 (95% CI, 0.83–1.69, p = 0.344).

In subgroup analyses (Fig 2), there was no evidence of effect modification for the association between NIV vs. IMV on hospital mortality regarding important antecedent characteristics–performance status, previous diagnosis of CHF and COPD—neither acute physiologic variables–non-respiratory SOFA ≥ 4, acute respiratory acidosis and Pao2/Fio2 ratio < 150 mmHg.

Fig 2. Subgroup analysis of the effect of noninvasive ventilation vs. invasive mechanical ventilation on hospital mortality.

Fig 2

The x-axis represents the odds ratio for the comparison of noninvasive ventilation (NIV) vs. invasive mechanical ventilation (IMV) according to the analyzed subgroup. SOFA: Sequential organ failure assessment; COPD: Chronic obstructive pulmonary disease.

Fig 3 presents the predicted probabilities of hospital mortality in each group across representative values. We observed a small difference in predicted hospital mortality by the initial ventilator strategy. However, there was a sharp increase in predicted mortality for higher non-respiratory SOFA scores. Within each non-respiratory SOFA score group, Pao2/Fio2 ratio ≤ 150 mmHg and, to a lesser extent, severe functional status impaired also changed the marginal probabilities of death.

Fig 3. Marginal probability of hospital mortality according to the initial strategy of mechanical ventilation and three major patient characteristics.

Fig 3

The x-axis represents the probability of the outcome (hospital mortality) according to representative values of covariates, stratified according to the initial strategy of mechanical ventilation (noninvasive ventilation or invasive mechanical ventilation). For example, a patient who was initially under noninvasive ventilation, with an intermediate NR-SOFA, not severely impaired and with a Pao2/Fio2 ratio ≤ 150 had a predicted probability of hospital mortality of 57%. MV: mechanical ventilation; PF: Pao2/Fio2 ratio; PS: performance status; NR-SOFA: non-respiratory sequential organ failure assessment; Low-NR SOFA represents a value of 0; intermediate represents a value of 4; high represents a value of 8.

In an as-treated analysis, 27 out of 232 patients (11.6%) of the NIV group were intubated within 24 hours of ICU admission and 37 out of the remaining 205 (18%) were intubated after 24 hours (Fig 1). Patients of the NIV group who did not need IMV during their ICU course had the lower odds of death (adjOR 0.52, 95% CI, 0.28–0.97, p = 0.039). By contrast, patients who were intubated after the first 24 hours of ICU admission had higher odds of death (adjOR 3.22, 95% CI, 1.21–8.55, p = 0.019) (S3 Table).

Discussion

Main findings

In this multicenter cohort study, NIV as the initial ventilatory strategy was not associated with lower hospital mortality among VOPs admitted to the ICU with CAP. We observed a significant degree of positive confounding, mainly explained by acuity variables included in the SOFA score. There was no strong evidence of effect modification regarding important subgroups of patients who usually benefit from NIV (COPD, heart failure) [12, 13] neither on those who usually have worse outcomes under NIV in this setting (Pao2/Fio2 < 150, higher non-respiratory SOFA scores) [4]. Results were robust to sensitivity analyses of the main model and the imputation model assumptions. Irrespective of the initial ventilatory strategy, mortality rates were high for patients who were ultimately intubated, especially in the context of high non-respiratory SOFA scores, low Pao2/Fio2 ratio and in patients who were intubated after the first 24 hours of ICU admission. We stress that these results should be interpreted as associations and should not imply causation, since residual confounding may still be an issue.

Relationship with the literature

The hospital mortality for VOPs admitted with CAP to the ICU is quite high. In our cohort, the overall hospital mortality was 55%. In the United States, the 30-day mortality of elderly (≥65 years-old) Medicare beneficiaries admitted with pneumonia to the ICU is of 36% [32], while for those who used NIV or IMV, 30-day mortality was 52.1% and 55.3%, respectively [33]. In the UK case-mix program, data from the early 2000’s show a hospital mortality of 50% regardless of age. In the study by Schortgen et al. [34], hospital mortality was 40% and 6-month mortality was 50% for VOPs undergoing NIV irrespective of the initial diagnosis. In this context, we primarily hypothesized that a less invasive strategy would benefit this high mortality target population, but our results were neutral.

One explanation is that the use of NIV in patients with high respiratory drive and high tidal volumes might be a matter of concern [35]. Recent evidence suggests that self-inflicted lung injury may occur through many mechanisms and could be an issue if one decides not to intubate and allow the patient to have substantial spontaneous respiratory efforts [36]. However, noninvasive ventilation is associated with reduced mortality in acute hypoxemic respiratory failure [37] and finding the patient who would be harmed by spontaneous breathing is still a matter of debate, though, including those under IMV [38].

An alternative explanation to our findings is that the strategy of mechanical ventilation may not have an impact on the outcome whatsoever if used within reasonable clinical grounds and considering that NIV is frequently used as ceiling therapy [34]. Valley et al. [33], in a large retrospective cohort of elderly (≥65 years) patients, showed that NIV was no better than IMV, with an absolute risk reduction in 30-day mortality of –0.7% (95% CI, -13.8–12.4, p = 0.92). Our results add to this literature in that we had more granular physiological data beyond ICD-9 codes and we could observe that acuity variables were the main confounders of this association and probably the main determinants of outcome. Although point-estimates did not differ much between NIV and IMV (Fig 3), there was an evident gradient of increased mortality from the confounding variables.

Another concern is that studies assessing NIV in patients with pneumonia have yielded varying results [3, 6, 33, 39], suggesting that NIV could even be harmful if applied to patients with a higher burden of non-respiratory organ dysfunctions or too hypoxemic [4, 5]. Our subgroup analyses assessing effect modification did not suggest this was the case. Point estimates were not worrisome, except for patients with a Pao2/Fio2 ratio ≤ 150, in whom the point estimate differed substantially showing increased harm in those who received NIV, although with a high degree of uncertainty. Although this is biologically plausible and has been shown to be a predictor of failure of NIV, any interpretation of these findings should be very cautious, given the usual low power of subgroup analyses.

Our results should also be interpreted accounting for a risk of misdiagnosis of pneumonia [40]. Common explanations for misdiagnosis include both acute exacerbations of COPD or pulmonary edema from congestive heart failure, which may be difficult to differentiate from pneumonia at patient presentation. Although misdiagnosis could have a potential to bias our results, it would probably do so towards positive associations favoring NIV, which was not the case in our sample. Having said that, we believe this situation actually reflects usual clinical practice and may enhance the generalizability of our findings [41].

Implications for practice

Our results suggest that a careful balance of benefits and harms of each strategy and the risks of NIV failure–and worse outcomes when in happens–should be weighed against patient’s values and preferences to decide the best course of action. Clinicians should not avoid using NIV as an initial strategy of ventilation if it is used within reasonable clinical grounds, since there was no strong signal of harm from this strategy. Furthermore, NIV use as ceiling therapy should still be regarded as an alternative to IMV when treatment limitations are in place. By contrast, clinicians should not avoid offering IMV for VOPs admitted with pneumonia, especially early during their ICU course. Nevertheless, the prognostic implications of the need for IMV should be considered, especially later during ICU stay and when the burden of extra-pulmonary organ dysfunction is higher and functional impairment is severe.

Strengths and limitations

Our manuscript has some strengths. The multicenter nature of our study with 11 ICUs from different hospitals and the real-world scenario with treatment limitations in place enhances the generalizability of our results. To account for the inherent risks of an observational study, we developed a causal DAG, which is an important step towards stronger inference and explicit selection of confounders [20], with sensitivity analyses to assumptions of the model being robust. Furthermore, we used multiple imputation to account for data missingness, a recommended approach that usually leads to less biased estimates while retaining higher statistical power [30, 31].

These results are also amenable to limitations. Although we collected data from 11 ICUs over four years, we might have had low power to detect an association of benefit for NIV over IMV, considering we observed a protective point-estimate on our adjusted models; however, we had enough data points to include the main confounders in the regression model without overfitting the data. Our data dates back to 2009–2012, which could be an issue, but except for prone positioning in severe acute respiratory distress syndrome [42], no other therapies appliable to very elderly patients [43] received a strong recommendation since then. We did not have data on pneumonia etiology and specific treatment, which might have an impact on outcome; nevertheless, we do not believe this would explicitly influence clinician’s decision to use NIV or IMV and would therefore not be in the DAG. We also did not have access to how NIV or IMV were specifically deployed, such as NIV mode and interfaces and how PEEP was titrated. Furthermore, there could be variability between hospitals because of expertise with NIV, which was not specifically addressed in our models. Hospital mortality may not be the best outcome to be assessed in this population, since long-term functional outcomes could be more valuable; unfortunately, we could not have access to such outcomes. Data on do-not-intubate orders were not explicitly available, although these are seldom used in Brazil and this could be partially captured when excluding patients under palliative care. We also did not have measures of arterial blood gases neither ventilatory variables after the start of NIV, which could provide more mechanistic insights to explain our results [5, 35].

Conclusions

In a real-world sample of very old patients with community-acquired pneumonia admitted to the intensive care unit, noninvasive ventilation as the initial strategy was not associated with lower hospital mortality when compared to invasive mechanical ventilation, but there was no strong signal of harm from its use. The main confounders of this association were both the severity of respiratory dysfunction and of extrapulmonary organ failures, which should be considered in the decision-making process during the management of very old patients with pneumonia in the intensive care unit.

Supporting information

S1 Checklist. STROBE statement checklist.

(DOCX)

S1 Fig. Directed acyclic graph.

COPD: Chronic obstructive pulmonary disease; HF: Heart failure; BMI: Body mass index; SOFAnresp: non-respiratory SOFA score; GCS: Glasgow coma scale. * This directed acyclic graph was built with the online version of DAGitty.

(TIF)

S2 Fig. Study sample flowchart*.

* Readmissions excluded from this flowchart.

(TIF)

S3 Fig. Kaplan-Meier survival plot through 28 days according to initial ventilatory strategy.

Hazard ratio from a Cox proportional hazards model without statistical adjustment.

(TIF)

S4 Fig. Adjusted survival plot through 28 days according to initial ventilatory strategy.

Hazard ratio from a Cox proportional hazards model adjusted for age, sex, SAPS3 score and modified frailty index (mFI).

(TIF)

S1 Table. Proportion of missing data among variables included in the model.

(DOCX)

S2 Table. Sensitivity analyses for the primary outcome.

(DOCX)

S3 Table. As-treated analysis for the primary outcome.

(DOCX)

S1 File. Additional methods.

(DOCX)

Acknowledgments

We would like to thank Leandro Utino Taniguchi, Pedro Caruso and Heraldo Possolo de Souza for their comments on a previous version of this manuscript. We would also like to thank Danilo Teixeira Noritomi for his support to start this project.

Data Availability

Due to privacy and data protection regulations in Brazil and considering that data refers to personal information of the participants which cannot be ensured to be anonymized, data cannot be made fully available. The data underlying the results presented in the study are available from Carlos Brandão (e-mail: Carbrandao@prestadores.amil.com.br) for researchers who meet the criteria for access to confidential data according to the Ethics Committee (contact via Comitê.etica@procardiaco.com.br).

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Laporte L, Hermetet C, Jouan Y, Gaborit C, Rouve E, Shea KM, et al. Ten-year trends in intensive care admissions for respiratory infections in the elderly. Ann Intensive Care. 2018;8(1):84 10.1186/s13613-018-0430-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Heyland D, Cook D, Bagshaw SM, Garland A, Stelfox HT, Mehta S, et al. The Very Elderly Admitted to ICU: A Quality Finish? Critical care medicine. 2015;43(7):1352–60. 10.1097/CCM.0000000000001024 [DOI] [PubMed] [Google Scholar]
  • 3.Stefan MS, Priya A, Pekow PS, Lagu T, Steingrub JS, Hill NS, et al. The comparative effectiveness of noninvasive and invasive ventilation in patients with pneumonia. Journal of critical care. 2018;43:190–6. 10.1016/j.jcrc.2017.05.023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Antonelli M, Conti G, Moro ML, Esquinas A, Gonzalez-Diaz G, Confalonieri M, et al. Predictors of failure of noninvasive positive pressure ventilation in patients with acute hypoxemic respiratory failure: a multi-center study. Intensive care medicine. 2001;27(11):1718–28. 10.1007/s00134-001-1114-4 [DOI] [PubMed] [Google Scholar]
  • 5.Al-Rajhi A, Murad A, Li PZ, Shahin J. Outcomes and predictors of failure of non-invasive ventilation in patients with community acquired pneumonia in the ED. Am J Emerg Med. 2018;36(3):347–51. 10.1016/j.ajem.2017.08.016 [DOI] [PubMed] [Google Scholar]
  • 6.Murad A, Li PZ, Dial S, Shahin J. The role of noninvasive positive pressure ventilation in community-acquired pneumonia. Journal of critical care. 2015;30(1):49–54. 10.1016/j.jcrc.2014.09.021 [DOI] [PubMed] [Google Scholar]
  • 7.Zampieri FG, Bozza FA, Moralez GM, Mazza DD, Scotti AV, Santino MS, et al. The effects of performance status one week before hospital admission on the outcomes of critically ill patients. Intensive care medicine. 2017;43(1):39–47. 10.1007/s00134-016-4563-5 [DOI] [PubMed] [Google Scholar]
  • 8.Zampieri FG, Colombari F. The impact of performance status and comorbidities on the short-term prognosis of very elderly patients admitted to the ICU. BMC Anesthesiol. 2014;14:59 10.1186/1471-2253-14-59 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Heyland DK, Garland A, Bagshaw SM, Cook D, Rockwood K, Stelfox HT, et al. Recovery after critical illness in patients aged 80 years or older: a multi-center prospective observational cohort study. Intensive care medicine. 2015;41(11):1911–20. 10.1007/s00134-015-4028-2 [DOI] [PubMed] [Google Scholar]
  • 10.Cilloniz C, Dominedo C, Pericas JM, Rodriguez-Hurtado D, Torres A. Community-acquired pneumonia in critically ill very old patients: a growing problem. Eur Respir Rev. 2020;29(155). 10.1183/16000617.0126-2019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Marik PE. Management of the critically ill geriatric patient. Critical care medicine. 2006;34(9 Suppl):S176–82. 10.1097/01.CCM.0000232624.14883.9A [DOI] [PubMed] [Google Scholar]
  • 12.Berbenetz N, Wang Y, Brown J, Godfrey C, Ahmad M, Vital FM, et al. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev. 2019;4:CD005351 10.1002/14651858.CD005351.pub4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Osadnik CR, Tee VS, Carson-Chahhoud KV, Picot J, Wedzicha JA, Smith BJ. Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;7:CD004104 10.1002/14651858.CD004104.pub4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Garrouste-Orgeas M, Tabah A, Vesin A, Philippart F, Kpodji A, Bruel C, et al. The ETHICA study (part II): simulation study of determinants and variability of ICU physician decisions in patients aged 80 or over. Intensive care medicine. 2013;39(9):1574–83. 10.1007/s00134-013-2977-x [DOI] [PubMed] [Google Scholar]
  • 15.Philippart F, Vesin A, Bruel C, Kpodji A, Durand-Gasselin B, Garcon P, et al. The ETHICA study (part I): elderly's thoughts about intensive care unit admission for life-sustaining treatments. Intensive care medicine. 2013;39(9):1565–73. 10.1007/s00134-013-2976-y [DOI] [PubMed] [Google Scholar]
  • 16.Wilson ME, Majzoub AM, Dobler CC, Curtis JR, Nayfeh T, Thorsteinsdottir B, et al. Noninvasive Ventilation in Patients With Do-Not-Intubate and Comfort-Measures-Only Orders: A Systematic Review and Meta-Analysis. Critical care medicine. 2018;46(8):1209–16. 10.1097/CCM.0000000000003082 [DOI] [PubMed] [Google Scholar]
  • 17.Vink EE, Azoulay E, Caplan A, Kompanje EJO, Bakker J. Time-limited trial of intensive care treatment: an overview of current literature. Intensive care medicine. 2018;44(9):1369–77. 10.1007/s00134-018-5339-x [DOI] [PubMed] [Google Scholar]
  • 18.Ranzani OT, Besen B, Herridge MS. Focus on the frail and elderly: who should have a trial of ICU treatment? Intensive care medicine. 2020;46(5):1030–2. 10.1007/s00134-020-05963-1 [DOI] [PubMed] [Google Scholar]
  • 19.Cilloniz C, Liapikou A, Martin-Loeches I, Garcia-Vidal C, Gabarrus A, Ceccato A, et al. Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia. PloS one. 2018;13(7):e0200504 10.1371/journal.pone.0200504 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Lederer DJ, Bell SC, Branson RD, Chalmers JD, Marshall R, Maslove DM, et al. Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals. Ann Am Thorac Soc. 2019;16(1):22–8. 10.1513/AnnalsATS.201808-564PS [DOI] [PubMed] [Google Scholar]
  • 21.Zampieri FG, Soares M, Borges LP, Salluh JIF, Ranzani OT. The Epimed Monitor ICU Database(R): a cloud-based national registry for adult intensive care unit patients in Brazil. Rev Bras Ter Intensiva. 2017;29(4):418–26. 10.5935/0103-507X.20170062 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Moreno RP, Metnitz PG, Almeida E, Jordan B, Bauer P, Campos RA, et al. SAPS 3—From evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission. Intensive care medicine. 2005;31(10):1345–55. 10.1007/s00134-005-2763-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive care medicine. 1996;22(7):707–10. 10.1007/BF01709751 [DOI] [PubMed] [Google Scholar]
  • 24.Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83. 10.1016/0021-9681(87)90171-8 [DOI] [PubMed] [Google Scholar]
  • 25.Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. The New England journal of medicine. 1997;336(4):243–50. 10.1056/NEJM199701233360402 [DOI] [PubMed] [Google Scholar]
  • 26.Zampieri FG, Iwashyna TJ, Viglianti EM, Taniguchi LU, Viana WN, Costa R, et al. Association of frailty with short-term outcomes, organ support and resource use in critically ill patients. Intensive care medicine. 2018;44(9):1512–20. 10.1007/s00134-018-5342-2 [DOI] [PubMed] [Google Scholar]
  • 27.Besen B, Romano TG, Nassar AP Jr., Taniguchi LU, Azevedo LCP, Mendes PV, et al. Sepsis-3 definitions predict ICU mortality in a low-middle-income country. Ann Intensive Care. 2016;6(1):107 10.1186/s13613-016-0204-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA: the journal of the American Medical Association. 2016;315(8):801–10. 10.1001/jama.2016.0287 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Norton EC, Dowd BE, Maciejewski ML. Marginal Effects-Quantifying the Effect of Changes in Risk Factors in Logistic Regression Models. JAMA: the journal of the American Medical Association. 2019;321(13):1304–5. 10.1001/jama.2019.1954 [DOI] [PubMed] [Google Scholar]
  • 30.Vesin A, Azoulay E, Ruckly S, Vignoud L, Rusinova K, Benoit D, et al. Reporting and handling missing values in clinical studies in intensive care units. Intensive care medicine. 2013;39(8):1396–404. 10.1007/s00134-013-2949-1 [DOI] [PubMed] [Google Scholar]
  • 31.White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30(4):377–99. 10.1002/sim.4067 [DOI] [PubMed] [Google Scholar]
  • 32.Valley TS, Sjoding MW, Ryan AM, Iwashyna TJ, Cooke CR. Association of Intensive Care Unit Admission With Mortality Among Older Patients With Pneumonia. JAMA: the journal of the American Medical Association. 2015;314(12):1272–9. 10.1001/jama.2015.11068 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Valley TS, Walkey AJ, Lindenauer PK, Wiener RS, Cooke CR. Association Between Noninvasive Ventilation and Mortality Among Older Patients With Pneumonia. Critical care medicine. 2017;45(3):e246–e54. 10.1097/CCM.0000000000002076 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Schortgen F, Follin A, Piccari L, Roche-Campo F, Carteaux G, Taillandier-Heriche E, et al. Results of noninvasive ventilation in very old patients. Ann Intensive Care. 2012;2(1):5 10.1186/2110-5820-2-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Carteaux G, Millan-Guilarte T, De Prost N, Razazi K, Abid S, Thille AW, et al. Failure of Noninvasive Ventilation for De Novo Acute Hypoxemic Respiratory Failure: Role of Tidal Volume. Critical care medicine. 2016;44(2):282–90. 10.1097/CCM.0000000000001379 [DOI] [PubMed] [Google Scholar]
  • 36.Yoshida T, Fujino Y, Amato MB, Kavanagh BP. Fifty Years of Research in ARDS. Spontaneous Breathing during Mechanical Ventilation. Risks, Mechanisms, and Management. American journal of respiratory and critical care medicine. 2017;195(8):985–92. 10.1164/rccm.201604-0748CP [DOI] [PubMed] [Google Scholar]
  • 37.Ferreyro BL, Angriman F, Munshi L, Del Sorbo L, Ferguson ND, Rochwerg B, et al. Association of Noninvasive Oxygenation Strategies With All-Cause Mortality in Adults With Acute Hypoxemic Respiratory Failure: A Systematic Review and Meta-analysis. JAMA: the journal of the American Medical Association. 2020. 10.1001/jama.2020.9524 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.van Haren F, Pham T, Brochard L, Bellani G, Laffey J, Dres M, et al. Spontaneous Breathing in Early Acute Respiratory Distress Syndrome: Insights From the Large Observational Study to UNderstand the Global Impact of Severe Acute Respiratory FailurE Study. Critical care medicine. 2019;47(2):229–38. 10.1097/CCM.0000000000003519 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Carrillo A, Gonzalez-Diaz G, Ferrer M, Martinez-Quintana ME, Lopez-Martinez A, Llamas N, et al. Non-invasive ventilation in community-acquired pneumonia and severe acute respiratory failure. Intensive care medicine. 2012;38(3):458–66. 10.1007/s00134-012-2475-6 [DOI] [PubMed] [Google Scholar]
  • 40.Daniel P, Bewick T, Welham S, McKeever TM, Lim WS, British Thoracic S. Adults miscoded and misdiagnosed as having pneumonia: results from the British Thoracic Society pneumonia audit. Thorax. 2017;72(4):376–9. 10.1136/thoraxjnl-2016-209405 [DOI] [PubMed] [Google Scholar]
  • 41.Klein Klouwenberg PM, Cremer OL, van Vught LA, Ong DS, Frencken JF, Schultz MJ, et al. Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: a cohort study. Critical care. 2015;19:319 10.1186/s13054-015-1035-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Guerin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, et al. Prone positioning in severe acute respiratory distress syndrome. The New England journal of medicine. 2013;368(23):2159–68. 10.1056/NEJMoa1214103 [DOI] [PubMed] [Google Scholar]
  • 43.Wood KA, Ely EW. What does it mean to be critically ill and elderly? Curr Opin Crit Care. 2003;9(4):316–20. 10.1097/00075198-200308000-00011 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Andrea Cortegiani

11 Nov 2020

PONE-D-20-32054

Noninvasive ventilation in very old patients with pneumonia and respiratory failure: a multicenter retrospective cohort study

PLOS ONE

Dear Dr. Besen,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

 Two authors, experts in the fields, rose several points that I ask you to address in the revised version of the manuscript.

Please submit your revised manuscript by Dec 17 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Andrea Cortegiani, M.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

4. For more information on PLOS ONE's expectations for statistical reporting, please see https://journals.plos.org/plosone/s/submission-guidelines.#loc-statistical-reporting. Please update your Methods and Results sections accordingly.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is a retrospective multicenter cohort study to evaluate the effect of initial mode of ventilation ( NIV vs IMV) in elderly severe CAP with acute respiratory failure. The major limitations of this study are related to data collected retrospectively from a resgistry for ICU quality improvement in Brasil some years ago ( 2009-2012).There is a lack of relevant information that difficult to have solid conclussions: pneumonia etiology, long-term outcomes,limitation of therapy,respiratory mechanics and gas-exchange evolution, standard treament according to new guidelines.Comments:

1. Quality control. Data were collected by trained nurses and regularly audit. Can you please indicate how this was done ? Did you performed a quality control of collected data by a different observer ?

2. Duration of mechanical ventilation. 11.6% of 232 initial NIV patients were intubated within 24 hours and 37/205 (18%) after 24 hours.What was the total duration of IMV and NIV ? A survival analysis during the first 7 days ( Kaplan Meir) adjusted by confounding factors of patients with only IMV, NIV without IMV and NIV with IMV could clarify the impact of NIV alone in outcome.NIV without IMV had an an OR 0.52 and IMV alone an OR 3.22 , both significative.

3. Previous functional status. What was the fragility in this cohort of VOP ? Some authors demonstrated that fragility and initial severity (SOFA) were the most important independent prognostic factors of outcome in VOP admitted to ICU.

4.Severity of acute hypoxic respiratory failure. What was the initial mode of ventilation according to the initial severity of hypoxemia ( mild, moderate and severe determinated by PaO2/FIO2 ) ? What was the short-term evolution of patients with a mild ARF ( PaO2/FIO2 200-300) among both groups with initial NIV or IMV ?

5. What was the tidal volume and driving pressure in boths groups during the first 24-48 hours?Some authors indicated the risk of self-inflicted lung injury during spontaneous ventilation

Reviewer #2: GENERAL COMMENTS

Thank you for allowing me to review this interesting manuscript. This is a multicenter retrospective real-world study on the mortality associated with noninvasive ventilation (NIV) use in elderly patients with community-acquired pneumonia (CAP). The manuscript deals with a poor explored but clinically relevant topic, given the current rise in the number of critically ill elderly patients due to the increased life expectancy and the consequent ethical challenges physicians face regarding aggressiveness of care and resource optimization. Clinicians’ decision about whether to escalate levels of respiratory support is often difficult also due to the modest scientific evidence to guide their choices; therefore, this manuscript may be relevant to clinical practice in supporting clinicians' estimates of patients’ outcomes.

SPECIFIC COMMENTS

The manuscript is well written and easy to read. The quality of written English is acceptable.

Title:

I would add “critically ill” in the title to immediately let the reader understand that the topic is very old patients in ICU settings. I would change as follow: Noninvasive ventilation in critically ill very old patients with pneumonia: a multicenter retrospective cohort study.

Background:

The background is well written and informative. However, I have some suggestions:

1) First sentence needs a reference. I would suggest using the following reference: Laporte L, Hermetet C, Jouan Y, et al. Ten-year trends in intensive care admissions for respiratory infections in the elderly. Ann Intensive Care 2018; 8: 84.

2) I would add a sentence emphasizing the high mortality of patients with CAP (line 56) citing this interesting reference from Plos One: Cillóniz C, Liapikou A, Martin-Loeches I, et al. Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia. PLoS One 2018; 13: e0200504.

3) Sentence in lines 59-60 needs reference.

4) I would like to point out this interesting and very recent review on the subject that should be considered as a reference in the background: Catia Cillóniz, Cristina Dominedò, Juan M. Pericàs, Diana Rodriguez-Hurtado, Antoni Torres Community-acquired pneumonia in critically ill very old patients: a growing problem. European Respiratory Review Mar 2020, 29 (155) 190126; DOI: 10.1183/16000617.0126-2019

Methods:

The methods used are appropriate for the retrospective design of the study. Study question is clearly stated and clinically relevant. Good data analysis utilizing a proper statistical analysis to answer research questions. However, I have some remarks:

1) There is no mention of the “type of NIV” applied (i.e. modes, interface) and settings, as well as no information on the application and titration of IMV and PEEP. Was low tidal volume ventilation assured to patients treated with IMV? I think that this information, if available, might be relevant since it is proved that adherence to low tidal volume ventilation strategy is important for reducing mortality. If these additional data are not available, this aspect should be acknowledged in the limitation section.

2) Did you record whether or not patients were sedated during NIV? If not, I think it is worth mentioning it, since most patients receiving NIV are managed usually without sedation.

3) Authors collected clinical information on very old patients with CAP treated with NIV or IMV in the past 8 to 11 years. I wonder if the clinical practice on these patients may be very different from recent years in light of the more recent published evidence. Can you comment on that?

4) I think it would be interested to consider differences in time to death between the two ventilator strategies.

Results:

1) My main concern is about the fact that the reference model (model 4) is based on a variable (P/F) that was missing in 161/369 (43.6%), as shown in supplementary table E1.

2) Figure 1: It is not very clear to me. The legend should be more detailed, especially in the definition of NIV Success within 24 h. As it is written now, it looks that definitions of success and failure are the same. Furthermore, in Figure 1: 17 out of 27 patients who fail NIV within the first 24 hours died. What happened to the other 10 patients? Did the patients who fail NIV in the first 24 hours escalate to IMV? This is not clear from the Figure. Also, in Figure 1: Is “No MV” intended as no (invasive or noninvasive) respiratory support? This is not very clear from the Figure and the legend. Please specify. Moreover, in Figure 1 please be consistent in reporting data as N (%) for each field.

Discussion:

The discussion is balanced. References are relevant and updated. Limitations of the study are well addressed by the authors and discussed enough in details, but I would recommend emphasizing some of them better:

1) Since it is a retrospective study, it is impossible to know whether there is a causal relationship between the use of NIV or IMV and mortality. This needs to be more stressed in the discussion.

2) The author should acknowledge that although they attempted to adjust for some case-mix variables, some residual confounding might still be present.

3) Different expertise with NIV among centers should be acknowledged as a possible limitation.

4) I think it is worthy of including and discussing the following references:

- Wood KA, Ely EW. What does it mean to be critically ill and elderly? Curr Opin Crit Care. 2003 Aug;9(4):316-20. doi: 10.1097/00075198-200308000-00011. PMID: 12883288.

- Schortgen F, Follin A, Piccari L, Roche-Campo F, Carteaux G, Taillandier-Heriche E, Krypciak S, Thille AW, Paillaud E, Brochard L. Results of noninvasive ventilation in very old patients. Ann Intensive Care. 2012 Feb 21;2(1):5. doi: 10.1186/2110-5820-2-5. PMID: 22353636; PMCID: PMC3306189.

Minor comments:

Line 55 please add a space before ref 1

Line 78 use reasons for instead of reasons of

Line 93 Please change 80 years-old with 80 years old

Line 94 Please change as main reason with as the main reason

Line 110 pneumonia severity index needs reference, please add the following citation:

Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336(4):243–250.doi:10.1056/NEJM199701233360402

Line 143 change extra pulmonary with extrapulmonary

Line 148 change imputation with imputations

Line 152 change interactions with interaction

Line 156 mimrgns??? Please clarify the typo

Line 161 Please change with years old

Line 255 case mix need an hyphen change into case-mix

Line 290 please add an article before generalizability

Please be consistent throughout the manuscript in referring to invasive mechanical ventilation as IMV.

Please use the term noninvasive ventilation consistently also in the figure legends and avoid non-invasive ventilation

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Jan 27;16(1):e0246072. doi: 10.1371/journal.pone.0246072.r002

Author response to Decision Letter 0


18 Dec 2020

Reviewer #1: This is a retrospective multicenter cohort study to evaluate the effect of initial mode of ventilation ( NIV vs IMV) in elderly severe CAP with acute respiratory failure. The major limitations of this study are related to data collected retrospectively from a registry for ICU quality improvement in Brazil some years ago (2009 - 2012). There is a lack of relevant information that difficult to have solid conclusions: pneumonia etiology, long-term outcomes, limitation of therapy, respiratory mechanics and gas-exchange evolution, standard treatment according to new guidelines.

Answer: We thank the reviewer for his/her time and effort in reviewing our manuscript and for his/her comments, which helped us improve our manuscript. We agree that the study has limitations, but nevertheless the methodology is as sound as it can be given the limitations of the data and we tempered our conclusions to the results.

Comments:

1. Quality control. Data were collected by trained nurses and regularly audit. Can you please indicate how this was done ? Did you performed a quality control of collected data by a different observer ?

Answer: This is a relevant question. During the deployment of this database in the network of hospitals, each hospital was designated a dedicated case manager nurse to collect data and upload it into the database. This data is therefore collected prospectively. Data was routinely checked for completion and for any relevant discrepancies. Whenever the case manager nurse had any doubts, the ICU director and a centralized chief nurse coordinator were available to clarify any issues. During the training to start data collection, a random check was performed by the ICU director and chief nurse (but we have no data on agreement). We tempered how we framed this in the manuscript, because this is nevertheless a retrospective study and any conclusions should be drawn given this limitation.

2. Duration of mechanical ventilation. 11.6% of 232 initial NIV patients were intubated within 24 hours and 37/205 (18%) after 24 hours. What was the total duration of IMV and NIV? A survival analysis during the first 7 days (Kaplan Meier) adjusted by confounding factors of patients with only IMV, NIV without IMV and NIV with IMV could clarify the impact of NIV alone in outcome. NIV without IMV had an an OR 0.52 and IMV alone an OR 3.22 , both significative.

Answer: Thank you for bringing up this issue. We do not have the total duration of NIV and IMV and unfortunately cannot present this data.

To account for what both reviewers have asked, we undertook a survival analysis truncated at 28 days. In this analysis, patients discharged alive were considered alive up to 28 days because of the risk of informative right-censoring. We present crude unadjusted Kaplan-Meier survival plots and a survival curve after a Cox model adjusted for age, sex, modified frailty index and SAPS3 score (because there are no missing data in these variables and no imputation model would be necessary). The figures S3 and S4 present the results of these analyses.

3. Previous functional status. What was the fragility in this cohort of VOP ? Some authors demonstrated that fragility and initial severity (SOFA) were the most important independent prognostic factors of outcome in VOP admitted to ICU.

Answer: This is indeed an important consideration. In our dataset, we had available the functional status of our patients as assessed by a three-category performance status categorization. As described in table 1, 31% of this very elderly cohort had severe functional impairment, i.e., they were completely dependent on others for their activities of daily living, while 32% had no functional impairment. This was well balanced between groups, with no statistically significant difference. Given that this is an important confounder, functional status was accounted for in our regression model and was part of our assumptions. Furthermore, although we did not have a frailty measure such as the fragility index or the clinical frailty scale, we derived the modified frailty index (mFI) (table 1), which is also a validated frailty scale to be used specially with database research (1). 45% of our sample was considered frail by the mFI and there was no between group difference in frailty status. Instead of using mFI in our regression model, we included performance status and other covariates (that are part of mFI) in the model to allow exploration of effect modification by subgroup analyses. Regarding the SOFA score, it is an important prognostic factor and it was accounted for in our regression model. To explore both these characteristics, we present in our manuscript the Figure 3, which explores what the reviewer has asked by using marginal probabilities of the outcome (hospital mortality). As the figure shows, P/F ratio < 150, high non-respiratory SOFA scores and performance status impairment all are important characteristics that are associated with increasing hospital mortality regardless of the ventilation strategy.

4. Severity of acute hypoxic respiratory failure. What was the initial mode of ventilation according to the initial severity of hypoxemia (mild, moderate and severe determined by PaO2/FIO2 ) ? What was the short-term evolution of patients with a mild ARF ( PaO2/FIO2 200-300) among both groups with initial NIV or IMV ?

Answer: Thank you for asking for clarification in this issue. We agree that stratifying the analysis according to PaO2/FIO2 ratio is an important issue. However, instead of stratifying in three categories as per ARDS severity (which we cannot state from our data since we cannot ascertain whether infiltrates were bilateral or not), we used the cut-off of 150 in our cohort because this is a common cut-off described for higher risk of NIV failure in the literature, as explained in the manuscript. We refer the reviewer to Figures 2 and 3 of the manuscript. Figure 2 shows a subgroup analysis according to illness severity. Although there is a potential signal of effect modification by P/F ratio (at the cut-off of 150), the results were not statistically significant. Figure 3 presents marginal probabilities of the outcomes given sets of covariates. For example, patients with low non-respiratory SOFA scores and not severely impaired had a probability of death of 27% if their P/F ratio was > 150 and 37% if their P/F ratio was ≤ 150 (in the NIV group). However, for patients in the IMV group, these probabilities were respectively 30% and 39%. Hospital mortality probabilities increase progressively based on performance status impairment, non-respiratory SOFA (a surrogate for increasingly more organ dysfunction) and severity of respiratory dysfunction assessed by the P/F ratio. They are not much different from each initial category of respiratory support. We believe this figure is very informative and can ease the clinical application of our results.

5. What was the tidal volume and driving pressure in both groups during the first 24-48 hours? Some authors indicated the risk of self-inflicted lung injury during spontaneous ventilation

Answer: We agree with the reviewer that these are important issues to be addressed, however these data (tidal volume and driving pressure) are not available in our dataset and neither can be retrieved. This is a limitation of our analysis, which was acknowledged in the limitations session and addressed in the discussion. Self-inflicted lung injury is still a concept under intense discussion in the current literature with no randomized clinical trial data backing up this hypothesis. We also addressed this in the discussion session, while acknowledging that our results still present protective point-estimates of NIV, compatible with a recent meta-analysis published in the literature (2).

Reviewer #2: GENERAL COMMENTS

Thank you for allowing me to review this interesting manuscript. This is a multicenter retrospective real-world study on the mortality associated with noninvasive ventilation (NIV) use in elderly patients with community-acquired pneumonia (CAP). The manuscript deals with a poor explored but clinically relevant topic, given the current rise in the number of critically ill elderly patients due to the increased life expectancy and the consequent ethical challenges physicians face regarding aggressiveness of care and resource optimization. Clinicians’ decision about whether to escalate levels of respiratory support is often difficult also due to the modest scientific evidence to guide their choices; therefore, this manuscript may be relevant to clinical practice in supporting clinicians' estimates of patients’ outcomes.

Answer: Thank you for your time and effort in reviewing our manuscript. Your comments allowed us to improve our manuscript substantially. We hope to have addressed them properly and we are open to further clarification if necessary.

SPECIFIC COMMENTS

The manuscript is well written and easy to read. The quality of written English is acceptable.

Answer: Thank you for your comments.

Title:

I would add “critically ill” in the title to immediately let the reader understand that the topic is very old patients in ICU settings. I would change as follow: Noninvasive ventilation in critically ill very old patients with pneumonia: a multicenter retrospective cohort study.

Answer: We agree with the reviewer that this could be a better wording for the title. We changed it accordingly.

Background:

The background is well written and informative. However, I have some suggestions:

1) First sentence needs a reference. I would suggest using the following reference: Laporte L, Hermetet C, Jouan Y, et al. Ten-year trends in intensive care admissions for respiratory infections in the elderly. Ann Intensive Care 2018; 8: 84.

2) I would add a sentence emphasizing the high mortality of patients with CAP (line 56) citing this interesting reference from Plos One: Cillóniz C, Liapikou A, Martin-Loeches I, et al. Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia. PLoS One 2018; 13: e0200504.

3) Sentence in lines 59-60 needs reference.

4) I would like to point out this interesting and very recent review on the subject that should be considered as a reference in the background: Catia Cillóniz, Cristina Dominedò, Juan M. Pericàs, Diana Rodriguez-Hurtado, Antoni Torres Community-acquired pneumonia in critically ill very old patients: a growing problem. European Respiratory Review Mar 2020, 29 (155) 190126; DOI: 10.1183/16000617.0126-2019

Answer: We have added the references accordingly. They are good uptodate references that further enhance the justification of this study and the knowledge gap to be addressed. Thank you for your suggestions.

Methods:

The methods used are appropriate for the retrospective design of the study. Study question is clearly stated and clinically relevant. Good data analysis utilizing a proper statistical analysis to answer research questions. However, I have some remarks:

Answer: Thank you for your considerations.

1) There is no mention of the “type of NIV” applied (i.e. modes, interface) and settings, as well as no information on the application and titration of IMV and PEEP. Was low tidal volume ventilation assured to patients treated with IMV? I think that this information, if available, might be relevant since it is proved that adherence to low tidal volume ventilation strategy is important for reducing mortality. If these additional data are not available, this aspect should be acknowledged in the limitation section.

Answer: This is indeed an important limitation. We did not have access to such data. We now acknowledged this in the limitations session.

2) Did you record whether or not patients were sedated during NIV? If not, I think it is worth mentioning it, since most patients receiving NIV are managed usually without sedation.

Answer: This is also an interesting issue, but we did not record how and if patients were sedated. However, sedation while on NIV is not a common practice in Brazil and we believe it probably does not influence our results. We therefore have made no changes to the manuscript regarding this comment.

3) Authors collected clinical information on very old patients with CAP treated with NIV or IMV in the past 8 to 11 years. I wonder if the clinical practice on these patients may be very different from recent years in light of the more recent published evidence. Can you comment on that?

Answer: This is indeed an interesting issue and a limitation of our analysis, given the time frame of our database. Although there could be differences in management, only two strategies had confirmatory clinical trial evidence of reduced mortality after 2009-2012, namely prone positioning for moderate-to-severe ARDS and ECMO. ECMO is only rarely deployed, still nowadays, for very elderly patients, given prognostic considerations. Prone positioning, as observed in the ART trial, a Brazilian trial in moderate-to-severe ARDS, was seldom used (10%) within a clinical trial and its uptake was and is still lagging clinical trial evidence. Therefore, we believe that, in spite of being relatively “old” data, our results can still be applied to current practice and to systematic reviews of high-quality observational studies. We added a statement to the limitation session acknowledging this issue.

4) I think it would be interested to consider differences in time to death between the two ventilator strategies.

Answer: Thank you for bringing up this issue. We agree with the reviewer that this is an interesting analysis. Our main concern is that we did not follow-up patients after hospital discharge, which could lead to informative right-censoring in a time-to-event (survival) analysis. Given your suggestion and Reviewer 1 suggestion, we decided to present this data in the manuscript, but in the supplementary material. We truncated the analysis at 28 days and we considered patients discharged alive as alive up to 28 days. We present both a crude analysis (Kaplan Meier survival curve with HR, 95% CIs and p-values from a Cox model) and an adjusted analysis (Survival plot after a multivariable Cox model adjusted for age, sex, modified frailty index and SAPS3 score [variables without any missing data and that fulfilled the proportional hazards assumption]). Relevant changes were done in the methods and results session. They are presented as sensitivity analyses.

Results:

1) My main concern is about the fact that the reference model (model 4) is based on a variable (P/F) that was missing in 161/369 (43.6%), as shown in supplementary table E1.

Answer: We agree with the reviewer that this may be an issue. We decided to present our main analysis as is because it allows further exploration of effect modification and how confounded the association of NIV with outcome is by a subset of relevant variables. We stress that the results of our sensitivity analyses to the multiple imputation analysis (both using (a) SAPS 3 as a global measure of physiological derangement, that includes P/F ratio, creatinine, platelets, Glasgow coma scale and pH; and (b) the complete case analysis) was in line with the primary outcome analyses and therefore does not change the substantive interpretation of our results. Furthermore, data missingness up to 50% is tolerable when using multiple imputation, as recommended by some authors (3, 4). We prefer to maintain the manuscript as is to allow better interpretability of results, but if the reviewer and/or the editor believe that other modelling strategy is preferable, we can change it properly.

2) Figure 1: It is not very clear to me. The legend should be more detailed, especially in the definition of NIV Success within 24 h. As it is written now, it looks that definitions of success and failure are the same. Furthermore, in Figure 1: 17 out of 27 patients who fail NIV within the first 24 hours died. What happened to the other 10 patients? Did the patients who fail NIV in the first 24 hours escalate to IMV? This is not clear from the Figure. Also, in Figure 1: Is “No MV” intended as no (invasive or noninvasive) respiratory support? This is not very clear from the Figure and the legend. Please specify. Moreover, in Figure 1 please be consistent in reporting data as N (%) for each field.

Answer: We have corrected the Figure 1 accordingly, trying to be consistent with the terminology of the manuscript as suggested by other comments. We specify success and failure separately (the definition of failure was the need for IMV in the first 24 hours of ICU stay). We hope the Figure is now clearer to understand. In the case further clarification is necessary, we will be happy to address them properly.

Discussion:

The discussion is balanced. References are relevant and updated. Limitations of the study are well addressed by the authors and discussed enough in details, but I would recommend emphasizing some of them better:

Answer: Thank you for your comments. We believe your considerations are relevant and we have changed the manuscript accordingly to account for them.

1) Since it is a retrospective study, it is impossible to know whether there is a causal relationship between the use of NIV or IMV and mortality. This needs to be more stressed in the discussion.

Answer: We agree with the reviewer. To make a strong message regarding this, the last statement of the statement of main findings now read as follows: “Our results should be interpreted as associations and should not imply causation, since residual confounding may still be an issue.” Furthermore, throughout the manuscript we always describe the results as associations and we refrain from wording that would imply causation. In the “Implications for practice” session, we mainly acknowledge the real-world data results of the strategy and the prognostic implications of confounders and disease course.

2) The author should acknowledge that although they attempted to adjust for some case-mix variables, some residual confounding might still be present.

Answer: We agree with the reviewer and we further acknowledge this issue in the discussion session as described above.

3) Different expertise with NIV among centers should be acknowledged as a possible limitation.

Answer: We agree with the reviewer and we acknowledge this also as a limitation.

4) I think it is worthy of including and discussing the following references:

Answer: We agree with the reviewer that these are good references to be included in the manuscript and enhance its value. We have included them accordingly where they fit better.

Minor comments:

Line 55 please add a space before ref 1

Line 78 use reasons for instead of reasons of

Line 93 Please change 80 years-old with 80 years old

Line 94 Please change as main reason with as the main reason

Line 110 pneumonia severity index needs reference, please add the following citation:

Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336(4):243–250.doi:10.1056/NEJM199701233360402

Line 143 change extra pulmonary with extrapulmonary

Line 148 change imputation with imputations

Line 152 change interactions with interaction

Line 161 Please change with years old

Line 255 case mix need an hyphen change into case-mix

Line 290 please add an article before generalizability

Answer: We have done all changes as suggested by the reviewer. Thank you for looking at our manuscript with such a high scrutiny.

Line 156 mimrgns??? Please clarify the typo

Answer: This is actually not a typo. It’s the Stata package used to derive marginal predictions after multiple imputation (mimrgns). We wrote in the session that it is a user-written command to avoid understanding it as a typo.

Please be consistent throughout the manuscript in referring to invasive mechanical ventilation as IMV.

Please use the term noninvasive ventilation consistently also in the figure legends and avoid non-invasive ventilation

Answer: We have reviewed the manuscript to be consistent in the wording of both expressions. Thank you for reviewing our manuscript with such detail.

References

1. Zampieri FG, Iwashyna TJ, Viglianti EM, Taniguchi LU, Viana WN, Costa R, et al. Association of frailty with short-term outcomes, organ support and resource use in critically ill patients. Intensive care medicine. 2018;44(9):1512-20.

2. Ferreyro BL, Angriman F, Munshi L, Del Sorbo L, Ferguson ND, Rochwerg B, et al. Association of Noninvasive Oxygenation Strategies With All-Cause Mortality in Adults With Acute Hypoxemic Respiratory Failure: A Systematic Review and Meta-analysis. JAMA : the journal of the American Medical Association. 2020.

3. Vesin A, Azoulay E, Ruckly S, Vignoud L, Rusinova K, Benoit D, et al. Reporting and handling missing values in clinical studies in intensive care units. Intensive care medicine. 2013;39(8):1396-404.

4. Madley-Dowd P, Hughes R, Tilling K, Heron J. The proportion of missing data should not be used to guide decisions on multiple imputation. J Clin Epidemiol. 2019;110:63-73.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Andrea Cortegiani

13 Jan 2021

Noninvasive ventilation in critically ill very old patients with pneumonia: a multicenter retrospective cohort study

PONE-D-20-32054R1

Dear Dr. Besen,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Andrea Cortegiani, M.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for answering all comments of reviewers and to improve your manuscript that unfortunately have some lack of information that could be interesting to confirm your conclusions . This was included in the limitations of the manuscript in the discussion section : old vs recent years, Vt, Driving Pressure, how PEEP , mode of ventilation and NIV interface were applied .The study can be the base for a prospective study in the future

Reviewer #2: The authors made the necessary changes and the manuscript has improved. I have no further comments or suggestions.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Acceptance letter

Andrea Cortegiani

18 Jan 2021

PONE-D-20-32054R1

Noninvasive ventilation in critically ill very old patients with pneumonia: a multicenter retrospective cohort study

Dear Dr. Besen:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Andrea Cortegiani

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. STROBE statement checklist.

    (DOCX)

    S1 Fig. Directed acyclic graph.

    COPD: Chronic obstructive pulmonary disease; HF: Heart failure; BMI: Body mass index; SOFAnresp: non-respiratory SOFA score; GCS: Glasgow coma scale. * This directed acyclic graph was built with the online version of DAGitty.

    (TIF)

    S2 Fig. Study sample flowchart*.

    * Readmissions excluded from this flowchart.

    (TIF)

    S3 Fig. Kaplan-Meier survival plot through 28 days according to initial ventilatory strategy.

    Hazard ratio from a Cox proportional hazards model without statistical adjustment.

    (TIF)

    S4 Fig. Adjusted survival plot through 28 days according to initial ventilatory strategy.

    Hazard ratio from a Cox proportional hazards model adjusted for age, sex, SAPS3 score and modified frailty index (mFI).

    (TIF)

    S1 Table. Proportion of missing data among variables included in the model.

    (DOCX)

    S2 Table. Sensitivity analyses for the primary outcome.

    (DOCX)

    S3 Table. As-treated analysis for the primary outcome.

    (DOCX)

    S1 File. Additional methods.

    (DOCX)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    Due to privacy and data protection regulations in Brazil and considering that data refers to personal information of the participants which cannot be ensured to be anonymized, data cannot be made fully available. The data underlying the results presented in the study are available from Carlos Brandão (e-mail: Carbrandao@prestadores.amil.com.br) for researchers who meet the criteria for access to confidential data according to the Ethics Committee (contact via Comitê.etica@procardiaco.com.br).


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES